Abstract：
BACKGROUND: This study aimed to compare the local recurrence, distant metastasis and disease-specific survival rates of patients with localized myxoid liposarcoma in the surgery and adjuvant chemotherapy group versus the surgery alone group.
METHODS: A total of 456 patients in the Japanese National Bone and Soft Tissue Tumour Registry database who had localized myxoid liposarcoma and underwent surgery and adjuvant chemotherapy or surgery alone between 2001 and 2019 were included in this retrospective study. The study adjusted for background differences between patients who underwent surgery and adjuvant chemotherapy (n = 228) or surgery alone (n = 228) using propensity score matching.
RESULTS: Univariate analysis showed no significant difference in local recurrence rate between the two groups (5-year local recurrence-free survival: 98.6% [95% confidence interval: 95.9-99.6] vs. 94.0% [95% confidence interval: 89.7-96.6], P = 0.052). Univariate analysis showed no difference in the incidence of distant metastases between the two groups (5-year distant metastasis-free survival: 80.5% [95% confidence interval: 73.9-85.8] vs. 75.1% [95% confidence interval: 67.7-81.2], P = 0.508). Univariate analysis showed no difference in disease-specific survival between the two groups (5-year disease-specific survival: 92.6% [95% confidence interval: 86.1-96.2] vs. 93.2% [95% confidence interval: 87.6-96.4], P = 0.804). In the high-risk group (n = 203) with high-grade tumours and tumour size ≥10 cm, there were no significant differences in the local recurrence, distant metastasis and disease-specific survival rates between the surgery and adjuvant chemotherapy group and the surgery alone group.
CONCLUSIONS: The effect of adjuvant chemotherapy on localized myxoid liposarcoma appears to be limited.
METHODS: A total of 456 patients in the Japanese National Bone and Soft Tissue Tumour Registry database who had localized myxoid liposarcoma and underwent surgery and adjuvant chemotherapy or surgery alone between 2001 and 2019 were included in this retrospective study. The study adjusted for background differences between patients who underwent surgery and adjuvant chemotherapy (n = 228) or surgery alone (n = 228) using propensity score matching.
RESULTS: Univariate analysis showed no significant difference in local recurrence rate between the two groups (5-year local recurrence-free survival: 98.6% [95% confidence interval: 95.9-99.6] vs. 94.0% [95% confidence interval: 89.7-96.6], P = 0.052). Univariate analysis showed no difference in the incidence of distant metastases between the two groups (5-year distant metastasis-free survival: 80.5% [95% confidence interval: 73.9-85.8] vs. 75.1% [95% confidence interval: 67.7-81.2], P = 0.508). Univariate analysis showed no difference in disease-specific survival between the two groups (5-year disease-specific survival: 92.6% [95% confidence interval: 86.1-96.2] vs. 93.2% [95% confidence interval: 87.6-96.4], P = 0.804). In the high-risk group (n = 203) with high-grade tumours and tumour size ≥10 cm, there were no significant differences in the local recurrence, distant metastasis and disease-specific survival rates between the surgery and adjuvant chemotherapy group and the surgery alone group.
CONCLUSIONS: The effect of adjuvant chemotherapy on localized myxoid liposarcoma appears to be limited.
摘要：
背景：本研究旨在比较局部复发，手术和辅助化疗组与单纯手术组相比,局部黏液样脂肪肉瘤患者的远处转移和疾病特异性生存率.
方法：在日本国家骨和软组织肿瘤注册数据库中，共有456例患者在2001年至2019年间接受了局部黏液样脂肪肉瘤并接受了手术和辅助化疗或仅接受手术。该研究使用倾向评分匹配对接受手术和辅助化疗（n=228）或单独手术（n=228）的患者之间的背景差异进行了调整。
结果：单因素分析显示两组间局部复发率无显著差异（5年无局部复发生存率：98.6%[95%置信区间：95.9-99.6]vs.94.0%[95%置信区间：89.7-96.6]，P=0.052)。单因素分析显示两组间远处转移的发生率无差异（5年无远处转移生存率：80.5%[95%置信区间：73.9-85.8]vs.75.1%[95%置信区间：67.7-81.2]，P=0.508）。单变量分析显示两组之间的疾病特异性生存率没有差异（5年疾病特异性生存率：92.6％[95％置信区间：86.1-96.2]vs.93.2%[95%置信区间：87.6-96.4]，P=0.804）。在高度肿瘤和肿瘤大小≥10cm的高风险组（n=203）中，局部复发没有显着差异，手术和辅助化疗组与单纯手术组之间的远处转移和疾病特异性生存率。
结论：辅助化疗对局部黏液样脂肪肉瘤的疗效似乎有限。
方法：在日本国家骨和软组织肿瘤注册数据库中，共有456例患者在2001年至2019年间接受了局部黏液样脂肪肉瘤并接受了手术和辅助化疗或仅接受手术。该研究使用倾向评分匹配对接受手术和辅助化疗（n=228）或单独手术（n=228）的患者之间的背景差异进行了调整。
结果：单因素分析显示两组间局部复发率无显著差异（5年无局部复发生存率：98.6%[95%置信区间：95.9-99.6]vs.94.0%[95%置信区间：89.7-96.6]，P=0.052)。单因素分析显示两组间远处转移的发生率无差异（5年无远处转移生存率：80.5%[95%置信区间：73.9-85.8]vs.75.1%[95%置信区间：67.7-81.2]，P=0.508）。单变量分析显示两组之间的疾病特异性生存率没有差异（5年疾病特异性生存率：92.6％[95％置信区间：86.1-96.2]vs.93.2%[95%置信区间：87.6-96.4]，P=0.804）。在高度肿瘤和肿瘤大小≥10cm的高风险组（n=203）中，局部复发没有显着差异，手术和辅助化疗组与单纯手术组之间的远处转移和疾病特异性生存率。
结论：辅助化疗对局部黏液样脂肪肉瘤的疗效似乎有限。
